$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000119312515186462 Filed on May 14, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$7.216M	$5.924M
YoY Change	21.81%	18.93%
Cost Of Revenue	$2.711M	$2.162M
YoY Change	25.39%	1.98%
Gross Profit	$4.505M	$3.762M
YoY Change	19.75%	31.54%
Gross Profit Margin	62.43%	63.5%
Selling, General & Admin	$4.728M	$3.269M
YoY Change	44.63%	24.3%
% of Gross Profit	104.95%	86.9%
Research & Development	$1.421M	$720.0K
YoY Change	97.36%	-28.0%
% of Gross Profit	31.54%	19.14%
Depreciation & Amortization	$165.0K	$106.0K
YoY Change	55.66%	-119.63%
% of Gross Profit	3.66%	2.82%
Operating Expenses	$8.607M	$6.151M
YoY Change	39.93%	68.98%
Operating Profit	-$1.391M	-$227.0K
YoY Change	512.78%	-70.9%
Interest Expense	$827.0K	-$550.0K
YoY Change	-250.36%	-3.51%
% of Operating Profit
Other Income/Expense, Net	-$54.00K	-$529.0K
YoY Change	-89.79%	5190.0%
Pretax Income	-$2.270M	-$1.300M
YoY Change	74.62%	-3.7%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.272M	-$1.304M
YoY Change	74.23%	-3.26%
Net Earnings / Revenue	-31.49%	-22.01%
Basic Earnings Per Share	-$0.19	-$1.29
Diluted Earnings Per Share	-$0.19	-$1.29
COMMON SHARES
Basic Shares Outstanding	11.81M	1.012M
Diluted Shares Outstanding	11.81M	1.012M

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.00M	$4.800M
YoY Change	712.5%
Cash & Equivalents	$38.99M	$5.128M
Short-Term Investments
Other Short-Term Assets	$700.0K	$1.800M
YoY Change	-61.11%
Inventory	$775.0K	$700.0K
Prepaid Expenses
Receivables	$1.800M	$2.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$42.30M	$9.500M
YoY Change	345.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.174M	$1.500M
YoY Change	44.93%
Goodwill	$12.01M
YoY Change
Intangibles	$6.650M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$100.0K
YoY Change	-100.0%
Total Long-Term Assets	$20.98M	$1.600M
YoY Change	1211.0%
TOTAL ASSETS
Total Short-Term Assets	$42.30M	$9.500M
Total Long-Term Assets	$20.98M	$1.600M
Total Assets	$63.28M	$11.10M
YoY Change	470.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.371M	$800.0K
YoY Change	71.38%
Accrued Expenses	$3.400M	$1.600M
YoY Change	112.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.056M	$5.500M
YoY Change	-80.8%
Total Short-Term Liabilities	$6.275M	$10.60M
YoY Change	-40.8%
LONG-TERM LIABILITIES
Long-Term Debt	$14.61M	$10.60M
YoY Change	37.82%
Other Long-Term Liabilities	$28.00K	$6.600M
YoY Change	-99.58%
Total Long-Term Liabilities	$14.64M	$17.20M
YoY Change	-14.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.275M	$10.60M
Total Long-Term Liabilities	$14.64M	$17.20M
Total Liabilities	$23.81M	$27.80M
YoY Change	-14.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.6M
YoY Change
Common Stock	$12.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.47M	-$16.70M
YoY Change
Total Liabilities & Shareholders Equity	$63.28M	$11.10M
YoY Change	470.06%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$2.272M	-$1.304M
YoY Change	74.23%	-3.26%
Depreciation, Depletion And Amortization	$165.0K	$106.0K
YoY Change	55.66%	-119.63%
Cash From Operating Activities	-$1.010M	$180.0K
YoY Change	-661.11%	-98.23%
INVESTING ACTIVITIES
Capital Expenditures	$364.0K	$19.00K
YoY Change	1815.79%	-96.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$360.0K	-$20.00K
YoY Change	1700.0%	-100.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.930M	-450.0K
YoY Change	-973.33%	-98.1%
NET CHANGE
Cash From Operating Activities	-1.010M	180.0K
Cash From Investing Activities	-360.0K	-20.00K
Cash From Financing Activities	3.930M	-450.0K
Net Change In Cash	2.560M	-290.0K
YoY Change	-982.76%	-83.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.010M	$180.0K
Capital Expenditures	$364.0K	$19.00K
Free Cash Flow	-$1.374M	$161.0K
YoY Change	-953.42%	-98.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11837866	shares
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4837000
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	120000
CY2014Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	239000
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11816796	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11816796	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1436429	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100133900	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.12
CY2015Q1	us-gaap	Share Price SharePrice	5.55
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	965404	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14609000
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	12000
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	439000
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	670807	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1436429	shares
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	458000
CY2015Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	216000
CY2015Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1810000
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6275000
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1371000
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161649000
CY2015Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1056000
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	39467000
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63277000
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201104000
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	378000
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	821000
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	488000
CY2015Q1	us-gaap	Liabilities Liabilities	23810000
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1295000
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1619000
CY2015Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	64000
CY2015Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	821000
CY2015Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	255000
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38985000
CY2015Q1	us-gaap	Goodwill Goodwill	12005000
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2174000
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	747000
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1639000
CY2015Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	1794000
CY2015Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	323000
CY2015Q1	us-gaap	Assets Assets	63277000
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3900000
CY2015Q1	us-gaap	Inventory Net InventoryNet	775000
CY2015Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	452000
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	471025	shares
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	8.88
CY2015Q1	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	147000
CY2015Q1	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	348000
CY2015Q1	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	90000
CY2015Q1	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	245000
CY2015Q1	us-gaap	Assets Current AssetsCurrent	42301000
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	1367000
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	272000
CY2015Q1	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	218000
CY2015Q1	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	188000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	722906	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031804	shares
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	525000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5128000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11803970	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11803970	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	471000
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	202000
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1616000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11135000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1128000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159375000
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5961000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41298000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	463000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5451000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61141000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200661000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	273000
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1074000
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	505000
CY2014Q4	us-gaap	Liabilities Liabilities	19843000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1684000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1684000
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	70000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1074000
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	241000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36431000
CY2014Q4	us-gaap	Goodwill Goodwill	12005000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1968000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	542000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2687000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	277000
CY2014Q4	us-gaap	Assets Assets	61141000
CY2014Q4	us-gaap	Inventory Net InventoryNet	686000
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	409000
CY2014Q3	cdna	Sale Of Stock Pursuant To Exercise Of Underwriters Over Allotment Option SaleOfStockPursuantToExerciseOfUnderwritersOverAllotmentOption	220000	shares
CY2015Q1	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0200	pure
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	40346000
CY2014Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	144000
CY2014Q4	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	146000
CY2014Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	318000
CY2014Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	54000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	11000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	76000
CY2015Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	20000000
CY2015Q1	cdna	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	90000
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	387500
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	503000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	250000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	344000
CY2013Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	467000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityPeriodIncreaseDecrease	-539000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1464000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	2552000
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	250000
CY2012	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	180000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M6D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0155	pure
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1011980	shares
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4068	pure
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6331619	shares
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-548000
CY2014Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	90000
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	29000
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	207000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-227000
CY2014Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1570000
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	58000
CY2014Q1	us-gaap	Reimbursement Revenue ReimbursementRevenue	14000
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-529000
CY2014Q1	us-gaap	Revenues Revenues	5924000
CY2014Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	456000
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1304000
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-177000
CY2014Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	5834000
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	153000
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	528000
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-452000
CY2014Q1	us-gaap	Cost Of Services CostOfServices	2162000
CY2014Q1	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	15000
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48000
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	6151000
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	720000
CY2014Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1474000
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-291000
CY2014Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2663000
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19000
CY2014Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1795000
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	163000
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	48000
CY2014Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-560000
CY2014Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0
CY2014Q1	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	17000
CY2015Q1	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2015-01-30
CY2015Q1	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Collaboration and License Revenue</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> </div>
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.42
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	CareDx, Inc.
CY2015Q1	dei	Trading Symbol TradingSymbol	CDNA
CY2015Q1	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.76
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1014000
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14374	shares
CY2015Q1	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.
CY2015Q1	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	423548	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0191	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	357075	shares
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xi) any impairment of long-lived assets including in-process technology and goodwill and (xii) legal contingencies. Actual results could differ from those estimates.</p> </div>
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11814467	shares
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2016-01-01
CY2015Q1	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	Principal amortization of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal amortization may be deferred until July 1, 2016 and payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain revenue milestones as described in the Loan Agreement.
CY2015Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.53
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	us-gaap	Debt Instrument Description DebtInstrumentDescription	The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-253000
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.58
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4104	pure
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2012525	shares
CY2015Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the three months ended March 31, 2015 and 2014, approximately 52%, and 50%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At March 31, 2015 and December 31, 2014 approximately 57% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at March 31, 2015 and December 31, 2014.</p> </div>
CY2015Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4549	shares
CY2015Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-827000
CY2015Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	120000
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	0
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	88000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1391000
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	180000
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	90000
CY2015Q1	us-gaap	Reimbursement Revenue ReimbursementRevenue	0
CY2015Q1	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	27000
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54000
CY2015Q1	us-gaap	Revenues Revenues	7216000
CY2015Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	11704000
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	364000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-2272000
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-893000
CY2015Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	7096000
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	280000
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	165000
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	8607000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1421000
CY2015Q1	cdna	Description Of Agreement Expected Expiration Year DescriptionOfAgreementExpectedExpirationYear	The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which is expected to occur in late 2014 or early 2015.
CY2014Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	119000
CY2015Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2023000
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised	0	shares
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2705000
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y5M19D
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved	0
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod	14374	shares
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance	0	shares
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	407000
CY2015Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-253000
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2554000
CY2015Q1	us-gaap	Cost Of Services CostOfServices	2711000
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3932000
CY2015Q1	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	0
CY2015Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	196000
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-364000
CY2015Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	15625000
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	242000
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	280000
CY2015Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-389000
CY2015Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	14000
CY2015Q1	cdna	Percentage Of Default Interest Payment PercentageOfDefaultInterestPayment	0.05	pure
CY2015Q1	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	29000
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P9Y4M13D
CY2015Q1	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2015Q1	cdna	Prepayment Penalty PrepaymentPenalty	0	pure
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	3.53
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted During Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedDuringPeriod	423548	shares

Files In Submission

Name	View Source	Status
0001193125-15-186462-index-headers.html	Edgar Link	pending
0001193125-15-186462-index.html	Edgar Link	pending
0001193125-15-186462.txt	Edgar Link	pending
0001193125-15-186462-xbrl.zip	Edgar Link	pending
cdna-20150331.xml	Edgar Link	completed
cdna-20150331.xsd	Edgar Link	pending
cdna-20150331_cal.xml	Edgar Link	unprocessable
cdna-20150331_def.xml	Edgar Link	unprocessable
cdna-20150331_lab.xml	Edgar Link	unprocessable
cdna-20150331_pre.xml	Edgar Link	unprocessable
d910768d10q.htm	Edgar Link	pending
d910768dex311.htm	Edgar Link	pending
d910768dex312.htm	Edgar Link	pending
d910768dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2015 Q1 Form 10-Q Financial Statement

#000119312515186462 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2015 Q1 Form 10-Q Financial Statement

#000119312515186462 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna